Skip to content

Pfizer And Protalix BioTherapeutics’ Orphan Drug Elelyso, Gaucher Disease, And Pharming: Fun Facts

November 2, 2012

       Pharming, by definition, is “the production of inexpensive, plant-based therapeutic proteins, antibodies, and vaccines”.  Orphan drug Elelyso (manufactured by Pfizer Protalix BioTherapeutics) receives FDA approval in May 2012 for the treatment of Type 1 Gaucher Disease.  It is the “1st biological drug produced inside modified plant cells to win FDA approval for a human disease”.   

       The fascinating August 9, 2012, article titled, “Pharmers Plow Their Way Towards Protein Success”, from Drug Discovery & Development is a great read. 

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: